A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
Public ClinicalTrials.gov record NCT06571045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
Study identification
- NCT ID
- NCT06571045
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 984 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 7, 2024 (Actual)
- Primary completion
- Jul 14, 2026 (Actual)
- Completion
- Dec 31, 2027 (Estimated)
- Last update posted
- Oct 14, 2026
2024 – 2027
United States locations
- U.S. sites
- 85
- U.S. states
- 28
- U.S. cities
- 81
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale | Scottsdale | Arizona | 85255 | — |
| Fayetteville, Arkansas | Fayetteville | Arkansas | 72703 | — |
| Springdale, Arkansas | Springdale | Arkansas | 72764 | — |
| Bakersfield, CA | Bakersfield | California | 93309 | — |
| Glendale, CA | Glendale | California | 91204 | — |
| Modesto, CA | Modesto | California | 95356 | — |
| Mountain View, CA | Mountain View | California | 94040 | — |
| Redlands, CA | Redlands | California | 92374 | — |
| Sacramento, CA | Sacramento | California | 95825 | — |
| Sacramento, CA | Sacramento | California | 95841 | — |
| Santa Ana | Santa Ana | California | 92705 | — |
| Colorado Springs, CO | Colorado Springs | Colorado | 80909 | — |
| Denver, Colorado | Denver | Colorado | 80210 | — |
| Danbury, CT | Danbury | Connecticut | 06810 | — |
| Manchester, CT | Manchester | Connecticut | 06042 | — |
| Waterford,CT | Waterford | Connecticut | 06385 | — |
| Deerfield Beach, FL | Deerfield Beach | Florida | 33064 | — |
| Fort Lauderdale, FL | Fort Lauderdale | Florida | 33308 | — |
| Fort Myers,FL | Fort Myers | Florida | 33912 | — |
| Gainesville, FL | Gainesville | Florida | 32607 | — |
| Orlando, Florida | Orlando | Florida | 32806 | — |
| Plantation, FL | Plantation | Florida | 33324 | — |
| Sarasota, FL | Sarasota | Florida | 34232 | — |
| Saint Petersburg, FL | St. Petersburg | Florida | 33711 | — |
| Tallahassee, FL | Tallahassee | Florida | 32308 | — |
| Tampa, FL | Tampa | Florida | 33609-4614 | — |
| Tampa, FL | Tampa | Florida | 33617 | — |
| Winter Haven, FL | Winter Haven | Florida | 33880 | — |
| Lemont, IL | Lemont | Illinois | 60439 | — |
| Springfield, Illinois | Springfield | Illinois | 62702 | — |
| West Des Moines, IA | West Des Moines | Iowa | 50266 | — |
| Lenexa, Kansas | Lenexa | Kansas | 66215 | — |
| Wichita, Kansas | Wichita | Kansas | 67214 | — |
| Portland, Maine | Portland | Maine | 04101 | — |
| Hagerstown, MD | Hagerstown | Maryland | 21740 | — |
| Springfield,MA | Springfield | Massachusetts | 01107 | — |
| Grand Rapids, Michigan | Grand Rapids | Michigan | 49546 | — |
| Minneapolis, MN | Minneapolis | Minnesota | 55435 | — |
| Madison, MS | Madison | Mississippi | 39110 | — |
| Bloomfield, NJ | Bloomfield | New Jersey | 07003 | — |
| Cherry Hill, NJ | Cherry Hill | New Jersey | 08034 | — |
| Liverpool, NY | Liverpool | New York | 13088 | — |
| Oceanside, NY | Oceanside | New York | 11572 | — |
| Rochester, NY | Rochester | New York | 14620 | — |
| Asheville, NC | Asheville | North Carolina | 28803 | — |
| Hickory, NC | Hickory | North Carolina | 28602 | — |
| Wake Forest, MC | Wake Forest | North Carolina | 27587 | — |
| Winston Salem, NC | Winston-Salem | North Carolina | 27103 | — |
| Cleveland, Ohio | Cleveland | Ohio | 44122 | — |
| Cleveland, OH | Cleveland | Ohio | 44130 | — |
| Youngstown, Ohio | Youngstown | Ohio | 44505 | — |
| Edmond, OK | Edmond | Oklahoma | 73013 | — |
| Portland, OR | Portland | Oregon | 97221 | — |
| Springfield, Oregon | Springfield | Oregon | 97477 | — |
| Bethlehem, PA | Bethlehem | Pennsylvania | 18017 | — |
| Erie, PA | Erie | Pennsylvania | 16507 | — |
| Beaufort, SC | Beaufort | South Carolina | 29902 | — |
| Florence, SC | Florence | South Carolina | 29501 | — |
| Ladson, SC | Ladson | South Carolina | 29456 | — |
| West Columbia, SC | West Columbia | South Carolina | 29169 | — |
| Germantown, TN | Germantown | Tennessee | 38138 | — |
| Hixson, Tennessee | Hixson | Tennessee | 37343 | — |
| Johnson City, Tennessee | Johnson City | Tennessee | 37604 | — |
| Knoxville, TN | Knoxville | Tennessee | 37922 | — |
| Nashville, TN | Nashville | Tennessee | 37203 | — |
| Abilene, TX | Abilene | Texas | 79606 | — |
| Amarillo, TX | Amarillo | Texas | 79106 | — |
| Amarillo, TX | Amarillo | Texas | 79109 | — |
| Arlington, TX | Arlington | Texas | 76012 | — |
| Austin, TX | Austin | Texas | 78705 | — |
| Beaumont, TX | Beaumont | Texas | 77707 | — |
| Bellaire, TX | Bellaire | Texas | 77401 | — |
| Dallas, TX | Dallas | Texas | 75231 | — |
| Fort Worth, TX | Fort Worth | Texas | 76104 | — |
| Katy, TX | Katy | Texas | 77494 | — |
| Plano, TX | Plano | Texas | 75075 | — |
| Round Rock, TX | Round Rock | Texas | 78681 | — |
| San Antonio, TX | San Antonio | Texas | 78240 | — |
| Schertz, Texas | Schertz | Texas | 78154 | — |
| The Woodlands, TX | The Woodlands | Texas | 77384 | — |
| Willow Park, TX | Willow Park | Texas | 76087 | — |
| Salt Lake City, Utah | Salt Lake City | Utah | 84107 | — |
| Lynchburg, VA | Lynchburg | Virginia | 24502 | — |
| Richmond, Virginia | Richmond | Virginia | 23235 | — |
| Spokane, WA | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06571045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2026 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06571045 live on ClinicalTrials.gov.